
According to a Bloomberg report on December 27, the US Appeals Court dismissed the securities fraud class-action lawsuit filed against Philip Morris International (PMI) by shareholders on December 26.
Investors' collective lawsuit against PMI primarily includes the following aspects:
Firstly, investors have doubts about the clinical research methods and results submitted by PMI to the US FDA regarding IQOS. They consider the company's claims regarding the research on IQOS, such as being "rigorous," "the best science," and "highly advanced," to be false representations.
Secondly, investors have expressed doubts about the statement regarding the projected sales of IQOS in Japan by PMI.
In the end, US Appeals Court rejects investors' concerns over the clinical research methods and results of IQOS, while also ruling that optimistic statements regarding Japanese sales performance are allowed as forward-looking statements.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.